AstraZeneca Pharma India Faces Rs 60.5 Crore Show Cause Notice for Alleged Overcharging

AstraZeneca Pharma India received a show cause notice from the National Pharmaceutical Pricing Authority (NPPA) on September 11, 2025, alleging overcharging for its 'Symbicort Turbuhaler' Inhalation Powder. The NPPA claims the company exceeded the notified ceiling price from April 2016 to July 2025, with the overcharged amount totaling Rs 60.50 crore plus interest. AstraZeneca disputes the claim and has 30 days to respond. The company stated that the overall financial implication cannot be determined at this stage.